Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Following use of race-neutral lung function equations, African American and Latino pediatric ...
Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback